What does 2PHARMA do?

2PHARMA is a wholesaler in Gent. Public Limited, started on 19 January 2007, 1 establishment.

What is the address of 2PHARMA?

The registered office of 2PHARMA is located at Kortrijksesteenweg 1091 box B, 9051 Gent.

Is 2PHARMA still active?

Yes. According to the CBE (29 October 2026) 2PHARMA is active, legal situation “Normale toestand”, started on 19 January 2007.

Is 2PHARMA registered on Peppol?

Yes, 2PHARMA is registered on the Peppol network with ID 0208:0886662746.

What is the enterprise number of 2PHARMA?

The enterprise number of 2PHARMA is BE0886662746.

When was 2PHARMA founded?

2PHARMA was founded on 19 January 2007.

Who are the directors of 2PHARMA?

According to the 2025 annual accounts, the directors of 2PHARMA are: SDV Consult BV, Aquitania BV, MD Consult BV.

Is 2PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 19 January 2007; 5 annual accounts filed, latest fiscal year 2025; 3 directors known from the annual account.

How much profit did 2PHARMA make in 2025?

2PHARMA posted a profit after taxes of € 120,628 in financial year 2025.

What is the revenue of 2PHARMA?

As a small company, 2PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 296,218.

2PHARMA (Public Limited) - Gent - BE0886662746

Dossier 2PHARMA, printed on 29 October 2026 from databakkes.be/en/0886662746/2pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Busy address KBO

20 other companies have their registered office at the same address; threshold 10.

Financials

Financial year 2025

2PHARMA from Gent, company number BE0886662746, closed financial year 2025 with a result of € 120,628 after tax. For that financial year 2PHARMA recorded a gross margin of € 296,218 and equity of € 779,467. Compared with financial year 2024, the result moved from € 83,988 to € 120,628. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 9, 2026.

What it is worth Growing

€ 779,467

▲ 18% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 120,628

▲ 44% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 756

▼ 77% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 404,467.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 275,989

▲ 15% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 67,325

▲ 266% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Revenue	€ 1,438,296 Revenue 2022: € 1,438,296 First fiscal year in the series	€ 1,642,236 Revenue 2023: € 1,642,236 ▲ 14% vs 2022 (€ 1,438,296) Favourable step	€ 1,252,796 Revenue 2024: € 1,252,796 ▼ 24% vs 2023 (€ 1,642,236) Unfavourable step	-
Gross margin	-	€ 33,005 Gross margin 2023: € 33,005 First fiscal year in the series	€ -251 Gross margin 2024: € -251 ▼ € 33,256 vs 2023 (€ 33,005) Unfavourable step	€ 296,218 Gross margin 2025: € 296,218 ▲ € 296,469 vs 2024 (€ -251) Favourable step	▲ € 296,469
Profit after taxes	€ 22,179 Profit after taxes 2022: € 22,179 First fiscal year in the series	€ 38,055 Profit after taxes 2023: € 38,055 ▲ 72% vs 2022 (€ 22,179) Favourable step	€ 83,988 Profit after taxes 2024: € 83,988 ▲ 121% vs 2023 (€ 38,055) Favourable step	€ 120,628 Profit after taxes 2025: € 120,628 ▲ 44% vs 2024 (€ 83,988) Favourable step	▲ 44%
Equity	€ 536,795 Equity 2022: € 536,795 First fiscal year in the series	€ 574,849 Equity 2023: € 574,849 ▲ 7% vs 2022 (€ 536,795) Favourable step	€ 658,838 Equity 2024: € 658,838 ▲ 15% vs 2023 (€ 574,849) Favourable step	€ 779,467 Equity 2025: € 779,467 ▲ 18% vs 2024 (€ 658,838) Favourable step	▲ 18%
Total debts	€ 546,412 Total debts 2022: € 546,412 First fiscal year in the series	€ 284,896 Total debts 2023: € 284,896 ▼ 48% vs 2022 (€ 546,412) Favourable step	€ 264,421 Total debts 2024: € 264,421 ▼ 7% vs 2023 (€ 284,896) Favourable step	€ 343,314 Total debts 2025: € 343,314 ▲ 30% vs 2024 (€ 264,421) Unfavourable step	▲ 30%
Cash	€ 94,166 Cash 2022: € 94,166 First fiscal year in the series	€ 3,363 Cash 2023: € 3,363 ▼ 96% vs 2022 (€ 94,166) Unfavourable step	€ 3,310 Cash 2024: € 3,310 ▼ 2% vs 2023 (€ 3,363) Unfavourable step	€ 756 Cash 2025: € 756 ▼ 77% vs 2024 (€ 3,310) Unfavourable step	▼ 77%
Retained profit	€ 161,795 Retained profit 2022: € 161,795 First fiscal year in the series	€ 199,849 Retained profit 2023: € 199,849 ▲ 24% vs 2022 (€ 161,795) Favourable step	€ 283,838 Retained profit 2024: € 283,838 ▲ 42% vs 2023 (€ 199,849) Favourable step	€ 404,467 Retained profit 2025: € 404,467 ▲ 42% vs 2024 (€ 283,838) Favourable step	▲ 42%
Balance sheet total	€ 1,083,207 Balance sheet total 2022: € 1,083,207 First fiscal year in the series	€ 859,745 Balance sheet total 2023: € 859,745 ▼ 21% vs 2022 (€ 1,083,207) Unchanged	€ 923,259 Balance sheet total 2024: € 923,259 ▲ 7% vs 2023 (€ 859,745) Unchanged	€ 1,122,781 Balance sheet total 2025: € 1,122,781 ▲ 22% vs 2024 (€ 923,259) Unchanged	▲ 22%

Key figures of 2PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to 2PHARMA?

What happened at 2PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2032 Aquitania BV stepped down as director. NBB
2032 MD Consult BV stepped down as director. NBB
Jul 9, 2026 New annual accounts for financial year 2025: profit of € 120,628 (▲ 44% vs 2024). Source: NBB ↗
2026 Aquitania BV became a director. NBB
2026 MD Consult BV became a director. NBB
2025 SDV Consult BV stepped down as director. NBB
2019 SDV Consult BV became a director. NBB
Jan 19, 2007 New establishment in Gent. KBO

In short

From € 22,179 profit in 2022 to € 120,628 profit in 2025.

Paid € 56,766 in corporate taxes since 2022.

Best year ever: 2025, with € 120,628 profit.

Original PDFs at the National Bank ↗

Management

2PHARMA HOLDING 100%

The stake of 2PHARMA HOLDING comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

2PHARMA

The shares are held by 2PHARMA HOLDING (100%).

Directors

According to the 2025 annual accounts

SDV Consult BV

Director · represented by Stanny De Vleeschauwer

Also active at: 2PHARMA HOLDING

since 2019 · until 2025

Aquitania BV

Director · represented by Anja Imschoot

Also active at: Ceres Pharmaceuticals, VESALE PHARMACEUTICA, b+pharma Belgium, DGPharma, Labophar, 2PHARMA HOLDING, MD Pharma, GLOBIFER INTL +1 more

since 2026 · until 2032

MD Consult BV

Managing director · represented by Mario Debel

Also active at: Ceres Pharmaceuticals, VESALE PHARMACEUTICA, 2PHARMA HOLDING, MD Pharma, Azur Medical, AUGMENTED ANATOMY, GLOBIFER INTL, CREDOPHAR

since 2026 · until 2032

Shareholders

2PHARMA HOLDING

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Kortrijksesteenweg 1091 box B

9051 Gent

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 20 companies are registered at this address.

All companies at this address →

Ceres Pharmaceuticals same network

€ 14.6 million revenue · 2025

What's Cooking Group

KOUTERLOS

€ 55,337 gross margin · 2024

b+pharma Belgium same network

€ 287,023 gross margin · 2025

DGPharma same network

€ 94,120 gross margin · 2024

+15 more

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0886.662.746
VAT number: BE 0886.662.746
Registered office: Kortrijksesteenweg 1091 bus B, 9051 Gent
Names & denominations: 2PHARMA
Enterprise type: Rechtspersoon
Legal form: Public limited company
Legal situation: Normale toestand
Start date: 19 January 2007
Peppol: Active · Active since 26 Aug 2025
Activities · NACE: Groothandel in farmaceutische en medische artikelen

View on CBE Public ↗ Annual accounts (NBB) ↗